GlassScriptPhysician profile
Jessica Gavzer
NPI 1902085673
$5,031.93
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $1,810 · 2023: $2,021 · 2024: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $982.85 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $544.03 | 2021-2024 | |
| Lilly USA, LLC | $406.05 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $380.11 | 2021-2023 | Prolia, Evenity |
| Pfizer INC. | $306.17 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.64 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $281.82 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $209.46 | 2021-2023 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $184.11 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $154.71 | 2022-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $151.35 | 2022 | |
| Merck Sharp & Dohme LLC | $107.24 | 2021-2023 | Vaxneuvance, Rotateq, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $100.68 | 2022-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $69.57 | 2021-2024 | |
| Exact Sciences Corporation | $60.86 | 2023 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Gavzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.